Sodium-Glucose Transporter 2
"Sodium-Glucose Transporter 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sodium-glucose transporter that is expressed in the luminal membrane of the PROXIMAL KIDNEY TUBULES.
| Descriptor ID |
D051297
|
| MeSH Number(s) |
D12.776.157.530.450.625.437.750 D12.776.157.530.500.750.750 D12.776.157.530.937.700 D12.776.543.585.450.625.562.750 D12.776.543.585.500.750.750 D12.776.543.585.937.825
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sodium-Glucose Transporter 2".
Below are MeSH descriptors whose meaning is more specific than "Sodium-Glucose Transporter 2".
This graph shows the total number of publications written about "Sodium-Glucose Transporter 2" by people in this website by year, and whether "Sodium-Glucose Transporter 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sodium-Glucose Transporter 2" by people in Profiles.
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
-
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555.
-
Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy. Nat Rev Nephrol. 2016 10; 12(10):583-4.
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73.
-
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009 Jun; 75(12):1272-1277.